Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroleptic malignant syndrome with risperidone

P P Gleason1, R L Conigliaro

  • 1Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania, USA.

Pharmacotherapy
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiofrequency ablation for chronic radiation proctitis: our initial experience with four cases.

Techniques in coloproctology·2014
Same author

Effects of two types of brief intervention and readiness to change on alcohol use in hazardous drinkers.

Journal of studies on alcohol·2001
Same author

Three questions can detect hazardous drinkers.

The Journal of family practice·2001
Same author

Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity.

Pharmacotherapy·2001
Same author

Changing physician prescribing behavior: the community-acquired pneumonia intervention trial.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

Losartan-induced cough after lisinopril therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Neuroleptic malignant syndrome (NMS) can occur with risperidone, even at low doses. This antipsychotic

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Neuroleptic malignant syndrome (NMS) is a rare but serious adverse reaction to antipsychotic medications, primarily linked to dopamine D2 receptor blockade in the basal ganglia.
  • Risperidone, an atypical antipsychotic, exhibits high serotonin 5-HT2 receptor blockade and dose-dependent dopamine D2 receptor blockade, which is theorized to reduce extrapyramidal symptoms (EPS).

Observation:

  • A case study involving a 73-year-old woman who developed NMS while on risperidone monotherapy.

Findings:

  • Despite risperidone's favorable profile for low extrapyramidal symptoms (EPS) at lower doses, this patient developed NMS.
  • The syndrome resolved upon discontinuation of risperidone and initiation of dantrolene and bromocriptine treatment.

Related Experiment Videos

Implications:

  • The protective effect of risperidone against EPS does not guarantee protection from NMS.
  • Clinicians should remain vigilant for NMS in patients treated with risperidone, regardless of dosage or perceived EPS risk.